MUC5AC and ductal breast carcinoma in situ: Interestingly enough, patients with Stage I of breast cancer and non-invasive ductal carcinoma in situ DCIS have demonstrated from 97 to 100% detection using the novel CLIA-CA-62 assay, when curability is the highest, while the mucin-based CA 15-3 ELISA assay was not (27% detection only for DCIS).